Early experience of thalidomide therapy for high-grade peripheral and facial arteriovenous malformations

CONCLUSIONS: We can conclude that thalidomide is able to reduce the symptom burden for patients with complex and proliferative AVMs that were refractory to established treatment modalities. Adverse effects are common, but the benefit achieved from taking thalidomide in otherwise treatment resistant cases outweighs the risks, most of which are manageable.PMID:37943292 | DOI:10.23736/S0392-9590.23.05111-8

Source: International Angiology - November 9, 2023 Category: Cardiology Authors: Lawrence Nip Nicholas Evans Suparna Bali Colin Hopper Anthie Papadopoulou Mohamed Khalifa George Hamilton Chung S Lim Jocelyn Brookes Source Type: research